BioSpace News Archive

“With this drug, we are not only preventing that first heart attack, but potentially the second stroke and maybe that third fatal event,” stated Deepak Bhatt, the study’s lead investigator.

UK-based Allergy Therapeutics markets three allergy “jabs” for tree pollen, dust mites, and grass pollen. Later this year it is planning results from a Phase I trial of a dust mite vaccine. But the company’s results from its trial for a birch pollen vaccine are a bit puzzling—the vaccine flunked the trial, but appeared to show positive results.

The company announced positive topline results from its Phase III EMPOWUR trial of viregron in patients with overactive bladder.

Wolters Kluwer, Health now equips astronauts at the National Aeronautics and Space Administration on board the International Space Station with the most current medical information and access to expert-authored recommendations.

labfolder is the first company amongst electronic laboratory notebook (ELN) and laboratory information management (LIMS) software vendors to announce its highly-ranked Net Promoter Score® (NPS®).

CytoDyn Inc., a late stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today announced that it has filed with the U.S. Food and Drug Administration the non-clinical portion of its Biologics License Application using the FDA’s Rolling Review process.

Soligenix, Inc. announced that they will be presenting at the National Institutes of Health - Commercialization Accelerator Program “FeedForward Session” in Washington, DC on March 21, 2019.

The FY19 Defense Appropriations Act provides $15 million to the Department of Defense Neurofibromatosis Research Program to support innovative, high-impact NF research.

The French company has an age limit for its top official and the company is working on a succession plan in anticipation of that change.

In the cannabis sector of drug development, there is a movement happening. And Rob Davidson, chief executive officer of CURE Pharmaceuticals is making sure his company is ready for the next steps.